Business Wire

NIKON-EUROPE

5.10.2021 06:02:13 CEST | Business Wire | Press release

Share
Nikon’s First European Nikon BioImaging Lab Now Open in Leiden

Nikon Europe B.V. has announced that its first European Nikon BioImaging Lab (NBIL) based in the prestigious Leiden Bio Science Park (LBSP) is now officially open.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005909/en/

The official opening took place on September 22nd with a welcome by Ziryan Othman, Team Leader Biotechnology Solutions, Nikon Europe Healthcare Division, followed by addresses by representatives of the organisations involved in helping Nikon Europe B.V. locate and develop the partnership with the Leiden Bio Science Park: Paul Dirkse, Vice Mayor of the City of Leiden; Hilde van der Meer, Commissioner, Netherlands Foreign Investment Agency; Chris van Voorden, Director Foreign Investments of InnovationQuarter; Ida Haisma, Director of Stichting Leiden Bio Science Park; Thijs de Kleer, Director of Biopartner Leiden, and Amito Haarhuis, Director of Rijksmuseum Boerhaave. Bo Kajiwara, Corporate Vice President, Nikon Corporation, Director & President, Nikon Europe B.V. led the opening program for Nikon Europe B.V.

The inauguration and ribbon cutting took place with a symbolic transfer of the famous 17th century van Leeuwenhoek’s microscope, by Amito Haarhuis. World famous for his pioneering work and discoveries in microscopy, Antonie van Leeuwenhoek developed this single-lens microscope, which proved capable of more powerful magnification than other lenses.

Takaharu Sasaoka, Director and Executive Vice President, Healthcare Business Head, Nikon Europe B.V., appreciates the symbolism of the microscope transfer, “It is very appropriate that Nikon, with over 100 years of expertise in optical technology, should open its first European Nikon BioImaging Lab (NBIL-Leiden) here in the Netherlands, the home of Antonie van Leeuwenhoek, the ‘father of microbiology’, whose systematic and extensive research laid the foundations of medical and scientific research. Our mission also is to advance healthcare and provide a better quality of life.

“We are very excited to be located here in the Leiden Bio Science Park, the largest life sciences cluster in the Netherlands, and I would like to thank all the organisations that helped Nikon Europe B.V. locate and develop this partnership. Following the success of our Nikon BioImaging Labs in the US and Japan, NBIL-Leiden will provide services for microscope-based imaging and analysis to the European biotech, pharma, and larger research communities. We are more than a core facility – our full-service capabilities include not only access to Nikon’s innovative microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.”

Daniel Ciepielewski, General Manager, Healthcare Division, Nikon Europe B.V., explains further, “NBIL-Leiden provides full-service imaging, data analysis, and cell cultures using cutting-edge Nikon microscope systems and software solutions, including the new laser scanning confocal AX R, the incubated high content imaging platform LIPSI, deep learning software NIS.ai, research inverted microscope Ti2-E, and compact live-cell imaging microscope BioStudio-T. Unlike other imaging facilities the lab offers full-service cell culture capabilities – our experienced staff is equipped to handle cell thawing, maintenance, expansion, differentiation, and other essential operations.

“The level of service and involvement of the lab is determined individually for each client based on need. Some need only access to equipment and are capable of data acquisition/analysis on their own, while others may require full-service imaging and analysis support. Additional applications include high content imaging and analysis, 3D imaging, fluorescence imaging, high-resolution imaging, color imaging, label-free imaging, cell screening and high throughput imaging, among others. NBIL-Leiden is now open, providing expert imaging support – on demand.”

Nikon Europe B.V. is grateful to InnovationQuarter, the regional economic development agency for the Province of Zuid-Holland, which assisted us in finding the right location and helped coordinate communication to develop the partnership with the Leiden Bio Science Park.

Nikon Europe B.V. is also grateful to the following contributing companies who have partnered with NBIL-Leiden: Clean Air Baker, PHC, Crest Optics, Photometrics, CoolLed, and Precipoint.

For further information, please contact: NBIL.EU@nikon.com
Or please visit www.microscope.healthcare.nikon.com/en_EU/products/cell-screening/nbil .

About Nikon Europe B.V.
Nikon Europe B.V. is the European microscopy arm of Nikon Healthcare Business Unit, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit www.microscope.healthcare.nikon.com/en_EU .

Link:

ClickThru

Social Media:

https://www.facebook.com/nikoninstrumentsinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye